Teaching Tool: Blood Pressure Classification

Slides:



Advertisements
Similar presentations
1 Mark Huffman, MD, MPH Northwestern University Feinberg School of Medicine Northwestern Memorial Hospital Healthy Transitions 21 November 2013 Blood Pressure.
Advertisements

THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)
Foos et al, EASD, Lisbon, 13 September 2011 Comparison of ACCORD trial outcomes with outcomes estimated from modelled and meta- analysis studies Volker.
CVD prevention & management: a new approach for primary care Rod Jackson School of Population Health University of Auckland New Zealand.
Special Diabetes Program for Indians Competitive Grant Program SPECIAL DIABETES PROGRAM FOR INDIANS Competitive Grant Program Clinical Goals for the Healthy.
Facts and Fiction about Type 2 Diabetes Michael L. Parchman, MD Department of Family & Community Medicine September 2004.
The concept of Diabetes & CV risk: A lifetime risk challenge
William B. Kannel, MD, FACC Former Director, Framingham Heart Study
AN ASSESSMENT OF THE PRIMARY PREVENTION CONTROL PROGRAM OF PHC PREVENTIVE CARDIOLOGY CLINIC AMONG PATIENTS AT RISK FOR CVD: A Retrospective Cohort Study.
Casablanca, le 30 Avril 2011 MEDITERANEAN GROUP FOR STUDY DIABETES.
Hypertension the Community - Overview HYPERTENSION IN THE COMMUNITY: OVERVIEW.
1 NHLBI/NEI National Institutes of Health NHLBI/NEI National Institutes of Health.
Copyleft Clinical Trial Results. You Must Redistribute Slides HYVET Trial The Hypertension in the Very Elderly Trial (HYVET)
Aim To determine the effects of a Coversyl- based blood pressure lowering regimen on the risk of recurrent stroke among patients with a history of stroke.
Long-term Cardiovascular Effects of 4.9 Years of Intensive Blood Pressure Control in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk.
2007 Hypertension as a Public Health Risk January, 2007.
December 02 1 Vascular mortality: Age-specific hazard ratios for 20 mmHg lower usual SBP deaths at ages
Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Effectiveness of Pharmacist Interventions on.
Date of download: 6/22/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Year in Hypertension J Am Coll Cardiol. 2006;48(8):
Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Usual Blood Pressure and Risk of New-Onset Diabetes:
Date of download: 9/17/2016 Copyright © The American College of Cardiology. All rights reserved. From: ACCF/AHA 2011 Expert Consensus Document on Hypertension.
Summary of “A randomized trial of standard versus intensive blood-pressure control” The SPRINT Research Group, NEJM, DOI: /NEJMoa Downloaded.
Antonio Coca, MD, PhD, FRCP, FESC
Dr John Cox Diabetes in Primary Care Conference Cork
Hazard ratio (& 95% CI) for 20 mmHg lower usual systolic BP
Blood Pressure and Lipid Trials: Rationale, Importance and Design
What should the Systolic BP treatment goal be in patients with CKD?
Nephrology Journal Club The SPRINT Trial Parker Gregg
Alcohol, Other Drugs, and Health: Current Evidence July–August 2017
a cautionary note from SPRINT
a cautionary note from SPRINT
The SPRINT Research Group
US cost-effectiveness of simvastatin in 20,536 people at different levels of vascular disease risk: randomised placebo-controlled trial UK Medical Research.
ACCORD Design and Baseline Characteristics
Hypertension guidelines What’s all the controversy about 2015
Hypertension in the Post SPRINT era
Copyright © 2015 American Medical Association. All rights reserved.
Blood Pressure and Age in Controlling Hypertension
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies  The Emerging.
Copyright © 2011 American Medical Association. All rights reserved.
Vanguard Phase Results for the Blood Pressure Component
Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) Trial Randomized, double-blind, placebo-controlled cardiovascular.
Should SPRINT change our practice?
Cholesterol Treatment Trialists’ (CTT) Collaboration Slide deck
REVEAL: Randomized placebo-controlled trial of anacetrapib in 30,449 patients with atherosclerotic vascular disease Louise Bowman on behalf of the HPS.
Pravastatin in Elderly Individuals at Risk of Vascular Disease
Copyright © 2007 American Medical Association. All rights reserved.
United States Preventive Services Task Force: Recommendations for ABPM
PS Sever, PM Rothwell, SC Howard, JE Dobson, B Dahlöf,
Risk factor thresholds: their existence under scrutiny
Cardiovascular risk factors: are they useful screening tests?
Systolic Blood Pressure Intervention Trial (SPRINT)
Progress and Promise in RAAS Blockade
Baseline characteristics of HPS participants by prior diabetes
The Hypertension in the Very Elderly Trial (HYVET)
A: Epidemiology update
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies  The Emerging.
Insights from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)
Prospective Studies Collaboration Lancet 2009; 373:
Diabetes Journal Club March 17, 2011
Lowering of SBP by 20 mm Hg Reduces Cardiovascular Risk by Half
Lipid-Lowering Arm (ASCOT-LLA): Results in the Subgroup of Patients with Diabetes Peter S. Sever, Bjorn Dahlöf, Neil Poulter, Hans Wedel, for the.
Originally presented by Drs. Daniel Levy, Richard H. Grimm, Steven E
The following slides are from a Cardiology Scientific Update in which Dr. Gordon Moe reported and discussed an original presentation by Drs. Bjorn Dahlof,
Clinician Referral Training
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies  The Emerging.
An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61
Simvastatin in Patients With Prior Cerebrovascular Disease: HPS
An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61
ROC curves for cardiovascular events, all-cause mortality, and disease progression. ROC curves for cardiovascular events, all-cause mortality, and disease.
Presentation transcript:

Teaching Tool: Blood Pressure Classification JAMA 2003;289:2560-2572

Systolic Blood Pressure Reduction The Lower, the Better [1/Lewington/ p 1912/C 1/P2/ ln 7-24, p 1903/C 2/p 1/ln 1-3, P 2/ln 1-2, Appendix A, References to Studies] Meta-analysis of 61 prospective, observational studies 1 million adults, 12.7 million person-years 7% reduction in risk of ischemic heart disease mortality 2 mmHg decrease in systolic blood pressure SLIDE SUMMARY: BP REDUCTION IS IMPORTANT; EVEN A LITTLE GOES A LONG WAY Perhaps most striking are the practical implications of these data: even a small, 2 mm Hg fall in mean systolic BP would be associated with large absolute reductions in premature deaths and disabling strokes.1 As shown here, a 2 mm Hg lower mean systolic BP could lead to a 7% lower risk of IHD death and a 10% lower risk of stroke death1 Data from a meta-analysis of 61 prospective, observational studies provide powerful evidence that throughout middle and old age, BP is strongly and directly related to vascular mortality.1 For example, a 10 mm Hg lower systolic BP is associated over the long term with a 40% lower risk of stroke death and a 30% lower risk of death from ischemic heart disease (IHD) or other vascular causes1 Within each decade of life between 40 and 89 years, the proportional difference in the risk of vascular death associated with a given absolute difference in mean BP is roughly equivalent down to at least 115 mm Hg for systolic BP and 75 mm Hg for diastolic BP (below this level there is little evidence). Thus, there was no evidence of a J curve across all middle and older age groups1 The investigators included studies in data on blood pressure, blood cholesterol, date of birth (or age) and sex had been recorded at baseline and in which a cause and date of death had been sought by study screeners. 33 of the studies were done in Europe (eg, the British Regional Heart Study, the Scottish Heart Health Study, the Tromso Study, assessing the association between blood pressure and serum lipids) 18 in North American or Australia (eg, the Atherosclerotic Risk in Communities Study, the Minnesota Heart Health Program) and 10 studies in China or Japan (eg, the Seven Cities China study on stroke prevention)1 10% reduction in risk of stroke mortality [1/Lewington/ p 1912/C 1/P2/ ln 7-24] [1/Lewington/ p 1903/Abstract/ Findings] Lancet 2002;360:1903-1913 [1/Lewington/p 1904/C 1/P 3/ln2-6, /Appendix A, Table A] Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-1913.

The Relationship between Systolic Blood Pressure and Macrovascular Mortality is Continuous and Increases with Age 1 2 4 8 16 32 64 128 256 1 2 4 8 16 32 64 128 256 80-89 yrs 80-89 yrs 70-79 yrs 70-79 yrs 60-69 yrs 60-69 yrs 50-59 yrs 40-49 yrs 50-59 yrs (Floating Absolute Risks and 95% CI) Stroke Mortality (Floating Absolute Risks and 95% CI) Cardiovascular Mortality Figure 2a: Stroke mortality rate in each decade of age versus usual SBP at the start of that decade. Rates are plotted on a floating absolute scale, and each square has area inversely proportional to the effective variance of the log mortality rate. 120 140 160 180 120 140 160 180 Systolic Blood Pressure (mmHg) Systolic Blood Pressure (mmHg) Lancet 2002;360:1903-1913

Observational Studies: Cardiovascular Mortality Doubles with Each 20/10mmHg Blood Pressure Increment Starting at 115/75 mmHg 8.0 8 JNC8 Goal 7 6 Cardiovascular Mortality Risk 4.0 5 4 2.0 3 1.0 2 1 Slide Summary According to a meta-analysis of over 60 prospective studies, the risk of cardiovascular mortality doubles with each rise of 20 mm Hg in systolic blood pressure (BP) and 10 mm Hg in diastolic BP. Background In a meta-analysis of 61 prospective, observational studies conducted by Lewington et al involving one million adults with no previous vascular disease at baseline, the researchers found that between the ages of 40-69 years, each incremental rise of 20 mm Hg systolic BP and 10 mm Hg diastolic BP was associated with a twofold increase in death rates from ischemic heart disease and other vascular disease. The researchers also noted that when attempting to predict vascular mortality risk from a single BP measurement, the average of systolic and diastolic BP was “slightly more informative” than either alone, and that pulse pressure was “much less informative.” The seventh report Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) notes this study result as yet more information linking hypertension to high risk for cardiovascular events. Lewington S, Clarke R, Qizilbash H, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2003;361:1903-1913. JNC 7. JAMA. 2003;289:2560-2572. 115/75 135/85 155/95 175/105 Systolic/Diastolic Blood Pressure (mmHg) Individuals aged 40-70 years, starting at blood pressure 115/75 mmHg Lancet 2002;360:1903-1913; JAMA 2003;289:2560-2572

Observational Studies: Increased Cardiovascular Mortality in Type 2 Diabetes Even at a Systolic Blood Pressure <120 mmHg 250 Non-diabetes patients Type 2 diabetes patients 200 JNC Goal 150 Cardiovascular Mortality Rate/10,000 person-yrs 100 ** 50 <120 120–139 140–159 160–179 180–199 ³200 Systolic Blood Pressure (mmHg) Why should we accept anything less than NORMAL in patients with type 2 DM? Diabetes Care 1993;16:434-444

Blood Pressure Arm, the Lower the Blood Pressure the Better! ADVANCE 5 Year Study: Blood Pressure Arm, the Lower the Blood Pressure the Better! J Am Soc Nephrol 2009;20:883-892

ADVANCE 10 Year Follow Up - Confirms Lower Blood Pressure Better Automated office blood pressure (AOBP) N Engl J Med 2014;371:1392-1406

Office-based semiautomated oscillometric BP ACCORD Study: Failed to Show Lowering Blood Pressure to <120 Reduce Major Fatal and Nonfatal CV Events; (+) Benefit Stroke Kaplan–Meier Analyses of Selected Outcomes. Shown are the proportions of patients with events for the primary composite outcome (Panel A) and for the individual components of the primary outcome (Panels B, C, and D). The insets show close-up versions of the graphs in each panel. In patients with type 2 diabetes at high risk for cardiovascular events, targeting a systolic blood pressure of less than 120 mm Hg, as compared with less than 140 mm Hg, did not reduce the rate of a composite outcome of fatal and nonfatal major cardiovascular events. Office-based semiautomated oscillometric BP N Engl J Med 2010;362:1575-1585

So Why Did the ACCORD Study Fail to Show a CVD Benefit to ↓ Blood Pressure? The study may have been underpowered. The event rate was only half of what was expected (~2%/year) and mean duration was only 4.7 years. The relatively wide confidence interval of 27% also diminished the power of the study. Aggressive treatment of other major CVD risk factors may have lowered the absolute risk to a point from where it was difficult to demonstrate further incremental benefit from more aggressive treatment of blood pressure. At the end of the study: - TC/HDL-C ratio = 3.60 - A1c = 7.6% - most patients were on aspirin - less patients were smoking